biostudies-literatureUnknown11(23)Palermos DCurrent lung cancer clinical research focuses on biomarkers and personalized treatment strategies. Adaptive clinical trial designs have gained significant ground due to their increased flexibility, compared to the conventional model of drug development from phase I to phase IV trials. One such adaptive approach is the seamless phase II/III design, which has been used to reduce the total sample size and drug development time. In this context, an algorithmic systematic search was conducted in MEDLINE (PUBMED), SCOPUS, EMBASE and Cochrane Central Register of Controlled Trials until 31 June 2022 in order to identify lung cancer trials of systematic treatments that have employed the seamless phase II/III methodology and to describe their characteristics. The search strategy yielded a total of 1Journal of clinical medicine7176https://www.ebi.ac.uk/biostudies/studies/S-EPMC9739886biostudies-literatureLung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review.PMC9739886Malandrakis PNtanasis-Stathopoulos IPsaltopoulou TTerpos EGavriatopoulou MSergentanis TNPalermos DfalseLung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review.Current lung cancer clinical research focuses on biomarkers and personalized treatment strategies. Adaptive clinical trial designs have gained significant ground due to their increased flexibility, compared to the conventional model of drug development from phase I to phase IV trials. One such adaptive approach is the seamless phase II/III design, which has been used to reduce the total sample size and drug development time. In this context, an algorithmic systematic search was conducted in MEDLINE (PUBMED), SCOPUS, EMBASE and Cochrane Central Register of Controlled Trials until 31 June 2022 in order to identify lung cancer trials of systematic treatments that have employed the seamless phase II/III methodology and to describe their characteristics. The search strategy yielded a total of 12022-01-01T00:00:00Z2022 Dec2025-04-20T03:33:22.612Z2025-04-20T03:33:22.612ZS-EPMC97398863649874910.3390/jcm11237176